These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33350054)

  • 21. The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study.
    Reich KM; Chang HJ; Rezaie A; Wang H; Goodman KJ; Kaplan GG; Svenson LW; Lees G; Fedorak RN; Kroeker KI
    Aliment Pharmacol Ther; 2014 Sep; 40(6):629-38. PubMed ID: 25039715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab as a second-line biological therapy in children with refractory ulcerative colitis.
    Volonaki E; Mutalib M; Kiparissi F; Shah N; Lindley KJ; Elawad M
    Eur J Gastroenterol Hepatol; 2015 Dec; 27(12):1425-8. PubMed ID: 26426835
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
    Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
    J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term Colectomy Rates of Ulcerative Colitis over 40 Years of Different Therapeutic Eras-Results from a Western Hungarian Population-based Inception Cohort Between 1977 and 2020.
    Wetwittayakhlang P; Gonczi L; Lakatos L; Kurti Z; Golovics P; Pandur T; David G; Erdelyi Z; Szita I; Lakatos PL
    J Crohns Colitis; 2023 May; 17(5):712-721. PubMed ID: 36539328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does anti-TNF therapy reduce the requirement for surgery in ulcerative colitis? A systematic review.
    Filippi J; Allen PB; Hébuterne X; Peyrin-Biroulet L
    Curr Drug Targets; 2011 Sep; 12(10):1440-7. PubMed ID: 21466486
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Impact of Biologic Therapies on Rate of Colectomy in Paediatric-onset Ulcerative Colitis - A Population-Based Cohort Study.
    Hope E; Kuronen-Stewart C; Wilson DC; Henderson P; Clark C
    J Pediatr Surg; 2024 Feb; 59(2):230-234. PubMed ID: 37981545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
    Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D
    Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016
    Kolehmainen S; Lepistö A; Färkkilä M
    Scand J Gastroenterol; 2019 Jun; 54(6):707-711. PubMed ID: 31136207
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis.
    McDermott E; Murphy S; Keegan D; O'Donoghue D; Mulcahy H; Doherty G
    J Crohns Colitis; 2013 Mar; 7(2):150-3. PubMed ID: 22520592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study.
    Shin JY; Park HM; Lee MY; Jeon JY; Yoo HJ; Ye BD
    Gut Liver; 2021 Nov; 15(6):867-877. PubMed ID: 33785664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the Optimal Position for Vedolizumab in the Treatment of Ulcerative Colitis: A Simulation Model.
    Scott FI; Shah Y; Lasch K; Luo M; Lewis JD
    Inflamm Bowel Dis; 2018 Jan; 24(2):286-295. PubMed ID: 29361100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.
    Nishio M; Ishii Y; Hashimoto Y; Otake H; Ogashiwa T; Tsuda S; Yasuhara H; Saigusa Y; Kimura H; Maeda S; Kunisaki R
    Scand J Gastroenterol; 2018; 53(10-11):1236-1244. PubMed ID: 30353757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
    Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
    Aliment Pharmacol Ther; 2016 Mar; 43(6):705-16. PubMed ID: 26762838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome of biological therapies in chronic antibiotic-refractory pouchitis: A retrospective single-centre experience.
    Verstockt B; Claeys C; De Hertogh G; Van Assche G; Wolthuis A; D'Hoore A; Vermeire S; Ferrante M
    United European Gastroenterol J; 2019 Nov; 7(9):1215-1225. PubMed ID: 31700634
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
    Christensen KR; Steenholdt C; Brynskov J
    Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
    Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
    Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study.
    Nørgård BM; Nielsen J; Qvist N; Gradel KO; de Muckadell OB; Kjeldsen J
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1301-9. PubMed ID: 22506582
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.